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Haemophilus ducreyi is the etiologic agent of chancroid, a sexually transmitted disease that increases the rate
of transmission of human immunodeficiency virus. Chancroid ulcerations are difficult to distinguish from
those produced by syphilis and herpes. Diagnosis based solely on clinical grounds is inaccurate, and culture
is insensitive. Highly sensitive PCR has largely superseded culture as the preferred method of laboratory
diagnosis; however, neither culture nor PCR is feasible where chancroid is endemic. We developed a rapid
(15-min) diagnostic test based on monoclonal antibodies (MAbs) to the hemoglobin receptor of H. ducreyi,
HgbA. This outer membrane protein is conserved in all strains of H. ducreyi tested and is required for the
establishment of experimental human infection. MAbs to HgbA were generated and tested for cross-reactivity
against a panel of geographically diverse strains. Three MAbs were found to be unique and noncompetitive and
bound to all strains of H. ducreyi tested. Using an immunochromatography format, we evaluated the sensitivity
and specificity of the test using geographically diverse strains of H. ducreyi, other Haemophilus strains, and
other bacteria known to superinfect genital ulcers. All H. ducreyi strains were positive, and all other bacteria
were negative, resulting in a specificity of 100%. The minimum number of CFU of H. ducreyi detected was 2 
106 CFU, and the minimum amount of purified HgbA protein detected was 8.5 ng. Although this level of
sensitivity may not be sufficient to detect H. ducreyi in all clinical specimens, further work to increase the
sensitivity could potentially make this a valuable bedside tool in areas where chancroid is endemic.
Chancroid, caused by the gram-negative bacterium Hae-
mophilus ducreyi (for reviews, see references 2, 47, and 60), is
one of the sexually transmitted genital ulcer diseases. Although
outbreaks are more prevalent in developing countries, sporadic
outbreaks have occurred in the United States. Up to 50% of
patients visiting sexually transmitted disease clinics in sub-
Saharan Africa may have chancroid (12, 23). Additionally, it is
an independent risk factor for the heterosexual transmission of
human immunodeficiency virus (HIV) (34; F. A. Plummer,
M. A. Wainberg, P. Plourde, P. Jessamine, L. J. DCosta, I. A.
Wamola, and A. R. Ronald, Letter, J. Infect. Dis. 161:810-811,
1990); therefore, the interest in chancroid has recently inten-
sified. In the last 10 years, several laboratories have begun to
define the molecular biology of this pathogen. The study of
virulence factors, the body’s immune response to infection, and
potential vaccines for H. ducreyi have all made significant con-
tributions to the understanding of this bacterium (3–10, 13–16,
22, 24, 26–28, 32, 33, 36, 38, 39, 46, 50, 53, 54, 59, 61, 64). With
the genome sequence completed, the process of annotation
will, undoubtedly, further accelerate progress on this strictly
human pathogen (www.microbial-pathogenesis.org).
At present, there are several laboratory methods for the
diagnosis of chancroid, including Gram stain, culture, and
PCR. Various rates of sensitivity have been reported for the
Gram stain, all approximating 50% (51, 57). The presence of
other organisms in the polymicrobial chancroid ulcer reduces
the specificity of the Gram stain, as these bacteria may be
confused with H. ducreyi morphologically, especially by inex-
perienced personnel. Thus, the Gram stain has little clinical
utility in the diagnosis of chancroid.
Before the advent of reliable PCR methods, culture was the
widely accepted standard of laboratory diagnosis (43, 57). H.
ducreyi is a fastidious bacterium that has an absolute require-
ment for heme because it lacks a heme biosynthetic pathway
(60); therefore, use of a special medium is required. Many
strains require the addition of fetal bovine serum for growth.
Furthermore, H. ducreyi requires a CO2 or microaerophilic
atmosphere, and its optimal growth temperature (33°C) is
lower than those of most human pathogens, mandating an
additional dedicated incubator if it is to be routinely cultured.
On primary isolation, small colonies of H. ducreyi usually ap-
pear after 2 to 3 days of incubation. Because ulcers are often
secondarily contaminated with other more rapidly growing
bacteria, cultures can be lost due to contamination (41). Cul-
ture is relatively insensitive, with the sensitivity ranging be-
tween 56 and 84% (25). The use of more than one primary
isolation medium improves isolation rates, but not substan-
tially (25). Culture is thought to be 100% specific; however,
traditional biochemical identification of a presumptive H. du-
creyi isolate is problematic due to its relative biochemical in-
ertness. Furthermore, H. ducreyi fails to grow on standard
biochemical media used to test other bacteria. Thus, for cul-
turing, optimum sensitivity and specificity require microbiolo-
gists with specific training and experience with H. ducreyi. Such
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personnel are lacking both in underdeveloped areas where the
organism is endemic and in developed countries such as the
United States where it is not endemic. Two advantages that
culture offers are the abilities to perform sensitivity testing of
isolates and strain typing for epidemiological studies. Despite
its limitations, culture will remain a valuable tool in the future.
As technology has improved, PCR has become the most
sensitive method for the diagnosis of chancroid (19, 40, 44, 58;
K. A. Orle et al., Abstr. 94th Gen. Meet. Am. Soc. Microbiol.
1995, abstr. C-247, p. 43, 1995). It has a sensitivity approaching
100%. Although some surmise that false-positive results occur,
this has been very difficult to prove. To date, PCR studies are
done in laboratories remote from the clinic setting and there-
fore are not useful for establishing a diagnosis in a time frame
that would benefit patient treatment. At present, multiplex
PCR is not available for commercial use; rather, it is used for
limited research purposes only.
The need to maintain trained personnel to perform and
interpret cultures and PCR in the resource-poor settings where
chancroid is endemic makes these tests economically prohibi-
tive. Furthermore, the costs of media, equipment, and reagents
for culture and PCR are considerable. Because of these limi-
tations, culture and PCR in their current formats are not suit-
able for on-site, immediate detection of H. ducreyi in clinical
specimens in areas where the organism is endemic. Therefore,
a stable, inexpensive, and rapid test that is simple to perform
and interpret at the bedside would be a valuable tool in chan-
croid control, so long as it maintains its sensitivity and speci-
ficity.
The immunochromatography (IC) test described in this re-
port is based on novel monoclonal antibodies (MAbs) to the
hemoglobin receptor, HgbA, which is an abundant outer mem-
brane protein (OMP) that is required for the acquisition of
heme from hemoglobin (26, 27; C. Elkins, unpublished data,
1999). The ability of H. ducreyi to obtain heme from hemoglo-
bin is required for pustule formation. An isogenic hgbA mutant
which is unable to utilize hemoglobin was unable to form
pustules in a human experimental model of infection (5). As
HgbA is conserved in geographically diverse isolates, we de-
veloped an IC test based on these MAbs to this protein. In the
present report, we describe progress in the initial development
of a rapid diagnostic test for H. ducreyi.
MATERIALS AND METHODS
Strains and media. All strains are described in Table 1. We used the exten-
sively characterized strain H. ducreyi 35000 for most of these studies. For routine
daily growth, H. ducreyi was maintained on chocolate agar plates prepared by the
University of North Carolina Hospitals Media Laboratory. The basal medium for
chocolate agar was gonococcal medium base containing 1% IsoVitaleX and 1%
autoclaved hemoglobin. Outer membranes were isolated as described previously
(26). For growth of H. ducreyi under heme-limiting conditions, we used gono-
coccal medium broth with IsoVitaleX and 1 g of hemin per ml for all strains
except hgbA mutant FX504 (27). For FX504 grown under heme-limiting condi-
tions, we used 5 g of hemin per ml. Neisseria gonorrhoeae (17) and Haemophilus
influenzae (21) (including typeable, nontypeable, and genital isolates of biotype
IV) were grown on gonococcal medium base agar plates with IsoVitaleX, 50 M
desferal, and 100 g of human hemoglobin per ml (18) under heme- and iron-
limiting conditions. Hemoglobin receptors of N. gonorrhoeae and H. influenzae
are subject to on-off phase variation. In order to select for the hemoglobin
receptor on-phase variants, these were grown on hemoglobin plates containing
the iron chelator desferal. Since this medium contains hemoglobin (heme) as the
sole source of iron, hemoglobin receptor off-phase variants do not grow on it,
thus ensuring that these bacteria would express a hemoglobin receptor. Staphy-
lococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212, Escherichia
coli ATCC 29522, Klebsiella pneumoniae ATCC 13883, Enterobacter aerogenes
ATCC 13048, and Bacteroides fragilis ATCC 25283 were all grown on 5% tryptic
soy sheep blood agar plates.
Production of MAbs. Female BALB/c mice (Charles River, Wilmington,
Mass.) were used as spleen donors for all fusions. HgbA was purified by affinity
purification on a hemoglobin agarose column as described previously (26), with
the following modification: HgbA was eluted from the agarose column with a
low-pH buffer in 1% octyl glucoside. HgbA liposomes were prepared as de-
scribed previously (29). HgbA liposome immunogen (5 g) was injected subcu-
taneously without adjuvant. Soluble HgbA immunogen (25 g in 1% octyl glu-
coside) was emulsified in Titermax adjuvant (CytRx Corporation, Norcross, Ga.)
and injected subcutaneously. Further intraperitoneal injections were given until
hyperimmunization was achieved. Hybridoma 1.51 was generated from a fusion
donor immunized with purified soluble H. ducreyi hemoglobin receptor in octyl
glucoside. Three hybridomas (hybridomas 4.23, 4.65, and 6.18) were generated
from a mouse immunized with liposomes containing HgbA. Sarkosyl-insoluble
OMPs from strain 35000 grown under heme-limiting conditions were used to
immunize the fusion mouse that generated hybridoma 9.76.
Standard polyethylene glycol (American Type Culture Collection, Manassas,
Va.)-mediated fusion techniques were used at the North Carolina State Univer-
sity Hybridoma Facility to generate the hybridomas used in this study. Briefly,
equal numbers of spleen cells were fused with the P3X63-Ag8.653 myeloma by
using 40% polyethylene glycol. Standard selection with hypoxanthine-aminop-
terin-thymidine (Sigma, St. Louis, Mo.) was used to generate hybridoma growth.
Enzyme-linked immunosorbent assays (ELISAs) and dot blot screening assays
were used to detect antigen-specific antibody during the fusion and cloning
procedures. Each hybridoma used in this study was cloned by limiting dilution,
which was repeated three times with one cell per well. During cloning proce-
dures, wells with antigen-specific antibody and a single isolated colony were
selected for further development. Static exhausted supernatant was generated
from each hybridoma and used for the various procedures described herein.
Commercially available radial immunodiffusion plates (Binding Site, San Diego,
Calif.) were used to isotype and quantitate static exhausted supernatants from
established murine hybridomas.
Purification of MAbs. Ascites was produced by standard techniques (37).
MAbs were purified on protein G columns (Pierce) according to the directions
of the manufacturer, followed by dialysis against phosphate-buffered saline
(PBS). Sodium dodecyl sulfate (SDS)-polyacrylamide gels stained with Coomas-
sie blue indicated a single immunoglobulin G (IgG) band of approximately 150
kDa under nonreducing conditions (data not shown). The protein concentration
was determined with a bicinchoninic acid assay kit from Pierce and was con-
firmed by Coomassie blue staining of SDS-polyacrylamide gels by comparison
with bovine serum albumin (BSA) standards.
Immunoprecipitation. We followed the presolubilized immunoprecipitation
method described by Gulig and Hansen (35), with the following modifications.
OMPs were obtained from strain 35000 grown under heme-limiting conditions.
For experiments with iodinated OMP, 100 g of OMP was iodinated as de-
scribed below for MAbs. OMP (100 g of iodinated OMP or 250 g of unlabeled
OMP) was solubilized with 1 ml of 2% Zwittergent 3,14 (Zw 3,14; Calbiochem-
Novabiochem, La Jolla, Calif.) in TEN (50 mM Tris, 100 mM NaCl, 5 mM
EDTA [pH 8.0]) (Zw/TEN) for 2 h at 37°C. Insoluble material was removed by
centrifugation at 14,000  g for 10 min. Each MAb was immobilized by mixing
100 l of a 50% protein G agarose slurry with 4 ml of each hybridoma super-
natant, whose pH had been adjusted with 1 ml of 1 M sodium acetate (pH 5.0).
After 1 h, the protein G agarose with the attached MAb was washed three times
with 0.1 M sodium acetate (pH 5.0) and finally one time with Zw/TEN. A total
of 100 l (containing 10 g of iodinated OMP or 25 g of unlabeled OMP) of
Zw/TEN-soluble OMP was diluted with 400 l of TEN to reduce the detergent
concentration. A total of 40 l of a 50% slurry of each protein G-immobilized
MAb was added and rocked overnight at 4°C. The slurry was washed three times
in 0.1% Zw/TEN and finally one time in TEN, changing tubes midway. After 75
l of reducing Laemmli sample buffer was added, each sample was boiled for 5
min and loaded onto SDS-polyacrylamide gels. For experiments in which iodin-
ated OMP was immunoprecipitated (see Fig. 1A), the gel was stained with
Coomassie blue, dried, and subjected to autoradiography at 20°C with an
intensifying screen. For experiments with unlabeled OMPs (see Fig. 1B), SDS-
polyacrylamide gels were transferred to nitrocellulose (NC) and Western blot-
ting was performed with affinity-purified anti-HgbA synthetic peptide IgG as
described previously (26).
Capture ELISA. None of the MAbs recognized HgbA under the denaturing
conditions used for Western blotting (data not shown). In order to evaluate
cross-reactivity, we developed a capture ELISA with the MAbs and a panel of H.
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ducreyi strains. Each MAb (purified IgG, 400 ng/well in 0.1 M carbonate buffer
[pH 9.6]) was coated onto Microtiter ProBond ELISA plates (Falcon), and the
plates were incubated at 4°C overnight. The plates were blocked for 1 h with 2%
BSA in PBS. Total cellular proteins from Zw 3,14-solubilized H. ducreyi strains
grown under heme-limiting conditions (108 CFU, about 25 g of protein) were
added to each well, and the plates were incubated overnight at 4°C. The plates
were washed three times with PBS–0.05% Tween, an affinity-purified anti-HgbA
peptide IgG (1:1,000) developed in rabbits (26) was added to each well, and the
plates were incubated for 2 h at room temperature (RT). The plates were
washed, and an anti-rabbit alkaline phosphatase-conjugated secondary antibody
(A8702 [1:2,000]; Sigma) was added and allowed to incubate for 1 h at RT. The
plates were washed and 100 l of 1 mg of para-nitrophenol phosphate (N-2765;
Sigma) per ml was added for detection. The plates were read after a 1-h incu-
bation at 37°C. The positive control was H. ducreyi strain 35000, and the negative




yr of isolation or typea Reference or source
b
H. ducreyi
8 HD 105 VDRL, Atlanta, Ga. 1962 26
18 NOHD New Orleans, La., 1989–1992 26
23 NOHD New Orleans, La., 1989–1992 26
26 NOHD New Orleans, La., 1989–1992 26
32 NOHD New Orleans, La., 1989–1992 26
34 HMC49 Jackson, Miss., 1994 or 1995 26
48 HMC47 Seattle, Wash., 1995 26
49 HMC86 Seattle, Wash., 1992 26
50 HMC87 Seattle, Wash., 1995 26
52 HMC89 Seattle, Wash., 1992 26
53 LA225 Los Angeles, Calif., 1982 26
54 LA228R Los Angeles, Calif., 1982 26
56 V 180 Rwanda, 1991 26
60 HMC39 England, 1982 26
62 HMC54 Dominican Republic, 1995 26
64 HMC56 Dominican Republic, 1995 26
65 HMC91 Raleigh, N.C., 1996 26
68 HMC90 Florida, 1989 26
71 HMC65 Kenya, 1984 26
73 CH2 Thailand, 1985 26
77 CH5 Thailand, 1985 26
81 ML067 Kenya, 1985 26
88 6V Atlanta, Ga. 26
112 HD342 CDC 26
H. influenzae
1861 Type A Peter Gilligan
Type B Peter Gilligan
1094 Type C Peter Gilligan
15992 Untypeable Peter Gilligan
12575 Untypeable Peter Gilligan
15504 Untypeable Peter Gilligan
15993 Untypeable Peter Gilligan
15991 Untypeable Peter Gilligan
597 Type IV genital strain Tim Murphy
756 Type IV genital strain Tim Murphy
799 Type IV genital strain Tim Murphy
1595 Type IV genital strain Tim Murphy
1610 Type IV genital strain Tim Murphy
6351 Type IV genital strain Tim Murphy
S. aureus ATCC 25923 Peter Gilligan
E. coli ATCC 29522 Peter Gilligan
N. gonorrhoeae
FA1090 P. Fred Sparling
FA19 P. Fred Sparling
E. faecalis ATCC 29212 Peter Gilligan
K. pneumoniae ATCC 13883 Peter Gilligan
E. aerogenes ATCC 13048 Peter Gilligan
B. fragilis ATCC 25283 Peter Gilligan
a VDRL, Venereal Disease Research Laboratory; CDC, Centers for Disease Control and Prevention.
b Peter Gilligan, University of North Carolina; Tim Murphy, Buffalo, N.Y.; P. Fred Sparling, University of North Carolina.
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control was hgbA mutant FX504. The ELISA plates were blanked against no-
antigen control wells.
Competition between MAbs. IgG was purified from hybridoma supernatants
with protein G according to the instructions of the manufacturer (Pierce). MAbs
were iodinated with Iodogen tubes (Pierce) according to the directions of the
manufacturers. A total of 2 mCi of sodium iodide (20 l of IMS-30 [Amersham]
diluted in 200 l of PBS) was activated for 6 min at RT. A total of 50 l of
activated iodine (0.5 mCi) was added to 100 g of each purified MAb (100 l of
each purified MAb at 1 mg/ml in PBS), and the mixture was incubated for 7 min.
The reaction was quenched with 50 l of saturated tyrosine for 5 min. Each MAb
was then desalted on a Bio-Gel P6 column (Bio-Rad). For competition experi-
ments, purified native HgbA (nHgbA) (200 ng/dot) was immobilized onto NC
membranes with a dot blot apparatus (Schleicher & Schuell). The membranes
were blocked with 2% BSA for 30 min. Dots were cut out and placed into a
24-well tissue culture dish. A total of 2.5 ml of 2% BSA in PBS containing
iodinated MAb, with or without a cold MAb competitor, was added, and the
mixture was gently rotated for 2 h. The molar ratio of unlabeled competitor MAb
with iodinated MAb was 50:1. The antibodies were removed, and the dots were
washed four times with Tris-buffered saline with 0.05% Tween. The dots were
taped to paper and exposed overnight to film by using an intensifying screen at
70°C. Each assay was done in duplicate on 2 separate days.
Preparation of IC test strips. MAbs 1.51 and 4.65 were purified from ascitic
fluid by standard affinity chromatography as described above. To develop the
rapid assay, 40 nm colloidal gold particles were generated by the reduction of
gold chloride with citric acid. After the particles were stabilized, the MAbs were
optimally conjugated and assessed as signal reagents. The unlabeled MAbs were
also immobilized to NC membranes (Millipore Corporation, Bedford, Mass.) for
assessment as capture reagents. They were then compared for their reaction
intensities with H. ducreyi and relative lack of reactivity with the H. influenzae
controls. The best combination was MAb 1.51 conjugated to colloidal gold and
MAb 4.65 immobilized to the NC membrane. An optimal concentration of MAb
4.65 was then applied in thin lines onto strips of NC (25 by 300 mm). A second
line of goat anti-mouse IgG (Dako, Carpinteria, Calif.) was sprayed onto the NC
at a 5-mm distance from the first line to serve as a procedural control. To
assemble the strips, materials including the NC membrane, sample application
pad (Ahlstrom Technical Specialties, Inc., Mt. Holly Park, Pa.), and sample
absorption pad (Whatman, Newton, Mass.) were attached as slightly overlapping
strips (25 by 300 mm) to plastic cards (75 by 300 mm; G&L Precision Diecutting,
San Jose, Calif.), from which 5-mm strips were cut. The strips are relatively stable
if they remain thoroughly desiccated and can be stored with dehumidification in
cylinders or in foil pouches at ambient temperatures until use.
Testing of IC test strips. All 26 H. ducreyi strains were grown overnight on
chocolate agar and suspended in PBS to an optical density at 600 nm of 0.2
(approximately 108 CFU/ml). A total of 100 l of this suspension was added to
100 l of detergent buffer (2% Triton X-100, 0.1% SDS, and 200 mM NaCl in
Tris-EDTA [pH 8.0]). The use of Zw 3,14 in this system produced false-positive
results, precluding its use. Triton X-100, like Zw 3,14, preserves the native
structure of HgbA (data not shown). Test strips were added, and chromatogra-
phy was allowed to proceed for 15 min at RT. The test strips were observed for
the presence of pink or purple lines. S. aureus, E. coli, E. faecalis, K. pneumoniae,
E. aerogenes, B. fragilis, and H. influenzae (including typeable, nontypeable, and
biotype IV genital isolates) were also tested, as were the two laboratory strains
of N. gonorrhoeae, FA19 and FA1090. A total of 14 strains of H. influenzae were
used, including 3 typeable, 5 untypeable, and 6 biotype IV genital strains. All the
bacteria, including the H. ducreyi laboratory strains and the non-H. ducreyi
bacteria, were tested once. The sensitivity of the strips was determined by using
fivefold dilutions of H. ducreyi strain 35000. The result was determined qualita-
tively after the assay was allowed to run for 15 min at RT. The appearance of two
lines was interpreted as a positive result, whereas the appearance of only one line
(the procedural control) was interpreted as a negative yet valid test result.
RESULTS
Background. Previously, we showed that we could solubilize
and purify HgbA antigen from H. ducreyi under nondenaturing
conditions using the detergent Zw 3,14 and hemoglobin aga-
rose, respectively (26). Ulcer samples are generally obtained
with swabs, and this suggested that we could release the HgbA
antigen from swabs using a detergent. Therefore, we used
native HgbA (nHgbA), purified under nondenaturing condi-
tions, as both the immunogen and the antigen in a screening
ELISA for the development of MAbs. We hypothesized that
any MAbs to native conformational epitopes on HgbA would
recognize HgbA released from swabs under nondenaturing
conditions and could then be detected by an IC format.
Development and confirmation of MAbs. A total of 2,400
wells from three fusions were screened by ELISA with purified
HgbA as the antigen. After subcloning and limiting dilutions,
five stable clones were obtained. Four MAb clones (clones
1.51, 4.23, 4.65, and 6.18) were studied in detail. MAb 1.51 was
of isotype IgG2b, and MAbs 4.23, 4.65, and 6.18 were of iso-
type IgG1. One clone (clone 9.76) was an IgM isotype and was
not further studied. After limiting dilution, we confirmed the
specificity of each MAb beyond the previous ELISA results, in
case the MAbs were reacting to a minor contaminant in the
HgbA preparation used to coat the ELISA wells. None of the
MAbs reacted in Western blots, precluding the use of this
technique to test the specificities of the MAbs (data not
shown). MAbs were therefore tested for binding to whole cells
of strain 35000 and to its isogenic hgbA mutant, strain FX504,
but again, no binding was observed (data not shown). We
surmised that the MAbs were binding to conformational
epitopes that were not surface exposed on intact H. ducreyi.
Because the MAbs recognized conformation-dependent
epitopes that were stable when HgbA was solubilized in Zw
3,14 in the ELISA format, we performed immunoprecipitation
experiments using Zw 3,14-solubilized OMP (Fig. 1). As seen
in Fig. 1A, by using iodinated OMP, each anti-HgbA MAb was
able to immunoprecipitate a 100-kDa protein. This 100-kDa
band was much enriched compared to its abundance in the
starting OMP material. Neither an irrelevant MAb (MAb
A4.70) (55) nor the no-MAb control (None in Fig. 1A) pro-
duced signals at the 100-kDa position. Minor nonspecific bind-
ing of other more abundant OMP bands was observed in all
lanes whether or not a MAb was present.
In order to confirm that the 100-kDa protein was HgbA, we
performed additional immunoprecipitation experiments using
unlabeled OMP as the antigen. Figure 1B shows a Western
blot in which we used an antibody prepared against a synthetic
peptide of HgbA that recognizes the denatured form of HgbA
(26). Each MAb immunoprecipitated a 100-kDa protein that
comigrated with purified HgbA and that was recognized by the
antipeptide HgbA antiserum. Immunoprecipitation done in
the absence of MAb yielded no bands at this position. Immu-
noprecipitation by MAb 1.51 in the absence of OMP yielded
smaller weakly reactive bands that presumably were of IgG
origin. HgbA was recognized only in the OMP antigen lane,
the purified HgbA lane, and the appropriate four MAb immu-
noprecipitate lanes. One limitation of immunoprecipitation is
the possibility of coprecipitation of complexes (35). It has been
shown that antibodies to lipooligosaccharide (LOS) can immu-
noprecipitate proteins. LOS, however, does not label under the
conditions that we used in this study. To test for reactivity to
LOS we performed dot blots in which purified HgbA, protein-
ase K-digested purified HgbA (39a), or purified LOS (42, 63)
was immobilized onto the NC. Each of the four MAbs bound
to purified HgbA but not to proteinase K-treated HgbA or to
the LOS (data not shown). A control LOS MAb (MAb 3E6)
(50, 52) recognized the LOS only. We concluded that the
MAbs specifically recognized HgbA, a conclusion that was
reconfirmed in subsequent experiments (see below).
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Use of capture ELISA. We used a capture ELISA method to
determine how broadly cross-reactive each MAb was to a geo-
graphically diverse panel of H. ducreyi isolates (Table 2).
Twenty-six laboratory strains (24) were grown under heme-
limiting conditions in order to induce expression of HgbA. All
four of the MAbs tested recognized laboratory strain 35000,
while none recognized FX504, the hgbA mutant. MAbs 1.51,
4.65, and 6.18 recognized all 26 strains. MAb 4.23, however,
recognized only 25 of 26 strains tested, resulting in a lower
mean value. MAb 4.23 did not recognize isolate 112. In the
course of experiments designed to explain this discrepancy, we
found that the deduced amino acid sequence of HgbA from
isolate 112 contains residues that are different from those of
hgbA in strain 35000 (Elkins, unpublished), including seven
contiguous residues between amino acids 438 and 444. This
variability most likely results in epitope alterations that prevent
recognition of HgbA by MAb 4.23. These results, in general,
confirm that the MAbs used for preparation of the IC strips are
able to detect diverse strains of H. ducreyi by capture ELISA.
MAb competition. Most detection methods require a cap-
ture and detection MAb to bind to separate epitopes on the
target antigen. We tested the four MAbs for binding to sepa-
rate epitopes by a competitive binding assay (Fig. 2). Each
MAb bound to the immobilized HgbA protein in the absence
of competitor. Each MAb also competed for binding to itself.
We found that MAb 4.65 could prevent the binding of MAb
4.23, but not vice versa. This suggested that MAbs 4.23 and
FIG. 1. Immunoprecipitation of HgbA by anti-HgbA MAbs.
(A) Zwittergent-solubilized iodinated OMP was incubated with pro-
tein G agarose containing immobilized MAb. Unbound material was
removed by washing. The samples were boiled in Laemmli sample
buffer and subjected to SDS-PAGE and Coomassie blue staining. The
gel was then dried and subjected to autoradiography. Lanes, from left
to right: 125I OMP, iodinated OMPs from strain 35000 (100 g); empty
lane; 1.51, 4.23, 4.65, and 6.18, anti-HgbA MAb immunoprecipitates;
A4.70, negative control MAb immunoprecipitate to RTX toxin (repeat
toxin) of N. meningitidis; None, immunoprecipitation performed in the
absence of MAb (negative control). (B). Zwittergent-solubilized unla-
beled OMP was subjected to immunoprecipitation as described above
and in the text. After SDS-PAGE the gel was subjected to Western
blotting with affinity-purified anti-HgbA synthetic peptide IgG. Anti-
rabbit alkaline phosphatase was used as the secondary antibody. 5-Bro-
mo-4-chloro-3-indolylphosphate–nitroblue tetrazolium was used for
detection. Lanes: OMP, strain 35000 OMP (5 g); purified native
HgbA from strain 35000 (200 ng); 1.51, 4.23, 4.65, and 6.18, MAb
immunoprecipitates obtained with the OMP antigen; None, immuno-
precipitation done in the absence of an MAb; No OMP, MAb 1.51
immunoprecipitation done in the absence of OMP antigen. Immuno-
precipitate lanes contained 20 l (20% of total) per lane.
FIG. 2. Competition between anti-HgbA MAbs. Purified HgbA
was immobilized onto an NC membrane (in duplicate) and probed
with each of the iodinated MAbs in the absence (none) or presence of
a 50-fold excess of each unlabeled MAb. After washing of the unbound
MAbs, the dot blots were exposed to film to detect binding to HgbA by
the labeled MAb.





testedc35000a FX504b Meand Ranged
1.51 2.05 0.094 2.15 1.77–2.56 26/26
4.23 0.62 0.005 0.43 0.05–1.23 25/26e
4.65 1.37 0.045 1.39 0.57–2.59 26/26
6.18 2.28 0.004 2.36 1.64–2.73 26/26
a Positive control strain 35000.
b Negative control strain FX504.
c Threshold for a positive result, 0.005.
d Mean and range for 26 experimental H. ducreyi strains.
e Isolate 112 was the only strain not recognized by MAb 4.23.
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4.65 bound to the same epitope or to closely spaced epitopes
and/or that the affinity of MAb 4.65 was greater than that of
MAb 4.23. However, other MAb combinations were noncom-
petitive. On the basis of the broadly cross-reactive nature of
the four MAbs and on our observation that three combinations
were noncompetitive, we proceeded to test these MAb pairs in
a first-generation format, IC.
Generation of IC test strips. IC relies on the migration of
soluble samples across the surface of an NC membrane. IC
tests typically use a labeled antibody (often conjugated to col-
loidal gold) that binds to the target antigen in solution. The
antigen-antibody complex migrates through the NC toward a
second antibody, immobilized in a line across the strip, that
captures this complex via a separate epitope on the antigen.
When the immobilized antibody captures the antigen-detec-
tion antibody complex, a visible colored line is generated. Pre-
liminary tests were done with various pairs of MAbs in the IC
test strips to determine the best combination. These results
revealed that use of MAb 1.51 as the detection MAb and MAb
4.65 conjugated to colloidal gold as the capture MAb gave the
strongest signal. The use of more than one MAb for either
detection or capture did not increase the sensitivity of the test
(data not shown).
Once the IC test strips were generated, H. ducreyi strain
35000 and its isogenic hgbA mutant, strain FX504, were tested,
and the results confirmed that the MAbs were directed against
HgbA. A positive reaction was obtained with strain 35000 but
not with strain FX504. These strains were used as controls in
all subsequent experiments.
Testing of IC. To examine the clinical utility of the IC test,
we tested a broad range of bacterial isolates (Table 1). As a
first step, we tested a diverse panel of laboratory-maintained
H. ducreyi clinical isolates in order to determine how broadly
reactive the MAbs were in the IC format. A total of 24 strains
were tested, in addition to laboratory strain 35000 and hgbA
mutant FX504. All strains gave a positive reaction (Fig. 3).
Having established the broad reactivity of these IC strips
against a diverse panel of H. ducreyi isolates, we next deter-
mined the specificity of the IC strips by testing their reactivity
against other pathogenic bacteria species. We tested S. aureus
and enteric gram-negative and anaerobic bacteria, including E.
coli, E. faecalis, K. pneumoniae, E. aerogenes, and B. fragilis, in
order to determine whether false-positive reactions might be
obtained from other bacteria commonly associated with skin
and bowel floras. In addition, hemoglobin receptor-expressing
N. gonorrhoeae and H. influenzae strains were tested to assess
the possibility that the MAbs might recognize other bacteria
containing related TonB-dependent hemoglobin receptors. Fi-
nally, we tested the reactivity of the IC test against the related
species H. influenzae. Because the species H. influenzae is a
heterogeneous group, we tested both typeable and nontype-
able clinical strains as well as isolates characterized as biotype
IV genital strains (Table 1). In contrast to the reactivity of this
test with all H. ducreyi strains, which were uniformly positive,
the IC test results for all non-H. ducreyi bacteria were indis-
tinguishable from the result for the negative control (strain
FX504) (specificity, 100%).
Having established the broad reactivity and specificity of the
IC test strips, we determined the sensitivity of the IC test
against purified HgbA protein and solubilized whole cells of
strain 35000. With serial dilutions, the limit of detection of
purified HgbA by this first iteration of the IC test was found to
be 8.5 ng/ml. Similarly, we found that the test could consis-
tently detect 2  106 CFU of H. ducreyi strain 35000 by limiting
dilution. Taken together, these results indicate that the IC test
has broad reactivity against a diverse panel of H. ducreyi
strains, is highly specific for H. ducreyi when it is tested against
other clinically relevant bacteria, and has moderate sensitivity
in its present configuration.
DISCUSSION
In this study we demonstrate the use of novel MAbs in an IC
format for the rapid, direct detection of H. ducreyi. Such a test
could be useful in resource-poor countries where chancroid is
endemic. These countries also have the highest prevalence of
HIV infections (20, 62). Therefore, the transmission of HIV
could potentially be decreased if chancroid were eliminated
(1). IC tests have been developed for other bacterial antigens
(11, 31) and have a number of advantages over conventional
microbiological techniques, including ease of performance,
stability in temperate climates, and comparatively low cost,
among many others. In the case of H. ducreyi, the greatest
advantage would be the rapidity of diagnosis of the etiology of
the genital ulcer. In making a rapid diagnosis, prompt, appro-
priate treatment could be instituted, thereby hastening the
time of curing the chancroid ulcer. In doing so, the spread of
HIV could be diminished.
IC relies upon the capture of an antigen by a labeled MAb
prepared against that specific antigen. A second immobilized
MAb, directed against a separate antigenic epitope, allows the
antigen-antibody complex to be concentrated and visually de-
FIG. 3. Detection of HgbA in clinical isolates by an IC test. H. ducreyi cells (108 CFU) were solubilized in detergent buffer, and a test strip was
placed into the test tube. After 15 min, the strips were observed for the presence of single or duplicate lines. The upper line is the positive control
line that contains a capture antibody (goat anti-mouse IgG) for detection of colloidal gold-conjugated MAb 1.51. The lower line contains
anti-HgbA capture MAb 4.65. The numbers above the lanes indicate the isolates described in Table 1; 35000, parent strain 35000 (positive control);
FX504, hemoglobin receptor mutant (hgbA) in a strain 35000 background (negative control).
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tected. In developing our IC test for H. ducreyi, the HgbA
receptor was chosen as the antigen because it is abundantly
expressed, it is readily purified for the development of anti-
gens, and it is antigenically and functionally conserved. It is
likely that naturally occurring mutants do not occur in vivo
because an isogenic mutant that does not synthesize HgbA was
unable to initiate an infection in the human model of chan-
croid (5). Furthermore, two studies have shown that HgbA is
expressed during natural infection (30, 56). Therefore, the
generation of MAbs to the HgbA protein seemed to be a
logical target.
To be clinically useful, an IC test strip must be able to
recognize a diverse panel of clinical isolates and have a high
specificity in order to distinguish between other related patho-
genic bacteria while it must maintain a sensitivity that is high
enough. We found that the MAbs used in our IC test were able
to accurately identify all laboratory strains of H. ducreyi tested.
These strains are broadly representative of the known patho-
genic strains of H. ducreyi (24). It is likely, therefore, that the
present configuration of the IC test will be useful in detecting
H. ducreyi under a variety of clinical circumstances and in a
variety of locations.
Using a limited panel of pathogenic bacteria, we also found
the test to be highly specific. As they are specific for the H.
ducreyi HgbA protein, the designated MAbs do not cross-react
with related TonB-dependent hemoglobin receptors found in
other bacteria, nor do the MAbs generate false-positive results
when they are tested against skin and genital commensal bac-
teria, but they are able to differentiate H. ducreyi from cryptic
genospecies of Haemophilus (biotype IV), which are also iso-
lated from genital sites.
This first-generation test maintains only a moderate level of
sensitivity. Similar IC tests, such as those for diphtheria toxin
(31) and Plasmodium falciparum HRP-2 antigen (11), have
greater sensitivities. Our IC test may have a lower sensitivity
due to its dependence upon the extraction of an OMP. Com-
pared to other antigens, OMPs may be more difficult to extract
and therefore may result in less antigen-antibody binding. In
testing laboratory strains, we used a 50/50 mixture of bacteria
and suspension buffer. The current detergent in the suspension
buffer may need to be altered to increase the level of extrac-
tion. During the course of developing the IC test, the original
suspension buffer that contained Zwittergent produced false-
positive results. The buffer was modified to contain Triton
X-100, another nondenaturing detergent. Other detergents
may result in the extraction of larger amounts of the HgbA
protein from the outer membrane.
The absolute number of H. ducreyi cells present in ulcers is
not known. One study on pustules (the lesion just prior to the
formation of ulcers) in an experimental human infection re-
ported that there were approximately 105 CFU per lesion (56).
Therefore, it is unclear what the minimum limit of detection is
that is needed to accurately detect a reasonable amount of the
HgbA released from H. ducreyi or what the number of organ-
isms is that are heme stressed in clinical specimens. It should
be noted, however, that the IC test is not dependent upon
viable organisms. The test is able to detect HgbA that has been
extracted from both viable and nonviable organisms. There-
fore, even if only nonviable organisms were sampled, the test
potentially could produce a positive result.
The test described is designed as a “proof of principle,” an
initial test to determine whether an immunologic assay with
the particular MAbs might be feasible for the diagnosis of H.
ducreyi infection. To increase the sensitivity, and therefore, to
provide greater clinical utility, the test may require modifica-
tions, perhaps by use of a different format. Nevertheless, the
MAbs used in this test demonstrated the required specificity,
noncompetitiveness, and cross-reactivity required for diagnos-
tic detection.
To date, all testing of this prototype IC test has used well-
characterized laboratory strain 35000 as well as clinical isolates
that have been frozen for up to 40 years rather than recently
obtained patient specimens. We envision testing of swabs of
future patient samples and then solubilization of the material
in suspension buffer. The swab would be briefly but vigorously
swirled to dislodge the specimen, pressed to the wall of the
tube to extract as much buffer as possible, and then discarded
prior to addition of the test strip. Such a study would require
confirmation and comparison with culture and PCR. As an
alternative to patient samples, swabs from experimental lesions
of rabbits or pigs infected with H. ducreyi could be used.
This IC test is a means to the rapid diagnosis of a genital
ulcer-causing disease that has been shown to increase the rate
of transmission of HIV (45). The test, which provides results in
as little as 15 min, would allow the treatment of H. ducreyi-
infected patients at their first visit. For HIV-positive patients,
reducing their infectivity for chancroid could, in turn, reduce
their infectivity for HIV. It has been shown that effective con-
trol of chancroid in core groups reduces or eliminates it in an
untreated noncore group population (48, 49; R. Steen et al.,
Int. Congr. Sex. Transm. Dis., 1999). In a study by Steen (48),
commercial sex workers were treated with the long-acting an-
tibiotic azithromycin. This treatment not only eliminated the
incidence of chancroid ulcerations in the core group (the com-
mercial sex workers), but chancroid was also eliminated in
their partners. Although the study was not designed to dem-
onstrate a decline in HIV transmission, computer modeling
suggested that 40 of 400 new cases of HIV were prevented in
the core group and 135 cases were prevented in their partners.
Thus, a targeted intervention may have broad-reaching effects
on the general population. Through rapid diagnosis and treat-
ment, our results suggest that this IC test method may prove to
be an important tool in the slowing of the spread of the sexu-
ally transmitted infection chancroid and, thus, HIV.
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